doi: 10.1001/archderm.1960.03730050146026.
Dosage requirements of griseofulvin in onychomycosis due to Trichophyton rubrum. I. Preliminary report
- PMID: 13816771
- DOI: 10.1001/archderm.1960.03730050146026
Item in Clipboard
Dosage requirements of griseofulvin in onychomycosis due to Trichophyton rubrum. I. Preliminary report
Arch Dermatol.
1960 May.
No abstract available
Similar articles
-
Therapy of onychomycosis by nail avulsion and topically applied griseofulvin.Arch Dermatol. 1962 Feb;85:276-8. doi: 10.1001/archderm.1962.01590020116015. Arch Dermatol. 1962. PMID: 13885342 No abstract available.
-
Preliminary results of a study to develop a treatment regimen for onychomycosis.J Am Podiatry Assoc. 1962 May;52:343-7. J Am Podiatry Assoc. 1962. PMID: 13876794 No abstract available.
-
Comparative effects of griseofulvin on onychomycosis and on psoriasis unguium.Arch Dermatol. 1960 May;81:838-40. doi: 10.1001/archderm.1960.03730050194035. Arch Dermatol. 1960. PMID: 13853232 No abstract available.
-
[Griseofulvin in tineas and onychomycoses].Arch Belg Dermatol Syphiligr. 1960 Dec;16:408-12. Arch Belg Dermatol Syphiligr. 1960. PMID: 13779913 French. No abstract available.
-
Griseofulvin.Med Clin North Am. 1970 Sep;54(5):1339-45. Med Clin North Am. 1970. PMID: 4248513 Review. No abstract available.
Cited by
-
Pharmacoeconomic analysis of oral antifungal therapies used to treat dermatophyte onychomycosis of the toenails. A US analysis.Pharmacoeconomics. 1998 Feb;13(2):243-56. doi: 10.2165/00019053-199813020-00007. Pharmacoeconomics. 1998. PMID: 10178650
-
Clinical and economic factors in the treatment of onychomycosis.Pharmacoeconomics. 1996 Apr;9(4):307-20. doi: 10.2165/00019053-199609040-00004. Pharmacoeconomics. 1996. PMID: 10160105 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
